Background Information

*Pneumocystis jirovecii* is an atypical fungus that causes *Pneumocystis* pneumonia (PCP) in patients with a compromised immune system. Transplant recipients and those with poorly controlled HIV are at highest risk, but those receiving chemotherapy for malignant diseases and others with immunosuppression may also develop the disease. PCP is an important cause of morbidity and mortality in immunocompromised patients.

The diagnosis of PCP is a challenge, since the microorganism does not grow in conventional culture. However, prompt and accurate detection of PCP is critically important for patient care, since the therapeutic agent used to treat patients with this infection is different from those employed for community-acquired pneumonia. Therefore, without an accurate diagnosis, the patient may be receiving inappropriate therapy.

Although direct examination of respiratory specimens has been used for years for the detection of *Pneumocystis*, these methods lack in sensitivity or specificity. Cleveland Clinic Laboratories' Department of Molecular Pathology and others have demonstrated that nucleic acid detection using *Pneumocystis*-specific primers and the polymerase chain reaction (PCR) is superior to conventional morphologic detection with respect to both sensitivity and specificity. Therefore, we now offer this method for the detection of *Pneumocystis* in respiratory specimens from patients at risk for this disease.

Clinical Indications

PCP is an opportunistic infection that can cause a lung infection in individuals with a weakened immune system, including those taking medications that may affect the immune system. The symptoms of PCP include breathing difficulties, fever and a dry cough. Other symptoms include fatigue, night sweats, weight loss and chest tightness. Antibiotics are usually recommended for those with mild, moderate or severe PCP. The key to surviving PCP is early treatment.

DNA PCR is useful in detecting the organism, tracking the course of infection and monitoring response to treatment.¹

Methodology

Amplification and detection of specimen using real-time, qualitative PCR comparing DNA taken from bronchial samples or sputum.

Interpretation

A positive result indicates the presence of *Pneumocystis* DNA.

A negative result indicates the absence of detectable *Pneumocystis* DNA.

Limitations of the Assay

Test result should aid in the diagnosis of pneumocystosis. When "rare" quantities are detected, then the possibilities of early infection, resolving infection or transient colonization should be considered.

Although a negative result does not entirely rule out the presence of PCP, the negative predictive value of this test is very high.
# Pneumocystis jirovecii PCR

<table>
<thead>
<tr>
<th>Test Overview</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test Name</strong></td>
<td><em>Pneumocystis jirovecii PCR</em></td>
</tr>
<tr>
<td><strong>Ordering Mnemonic</strong></td>
<td>PCPPCR</td>
</tr>
<tr>
<td><strong>Methodology</strong></td>
<td>Polymerase Chain Reaction (PCR)</td>
</tr>
<tr>
<td><strong>Reference Range</strong></td>
<td>Negative for <em>Pneumocystis jirovecii pneumoniae</em></td>
</tr>
<tr>
<td><strong>Specimen Requirements</strong></td>
<td>Testing Volume/Size: 1 mL; Type: Bronch (BAL); Induced Sputum: Bronchial Washing; Tissue from Lung. Container: Sterile container; Transport Temperature: Refrigerated.</td>
</tr>
<tr>
<td><strong>Minimum Specimen Requirements</strong></td>
<td>Volume/Size: 1 mL</td>
</tr>
<tr>
<td><strong>Alternate Specimen Requirements</strong></td>
<td>Testing Volume/Size: 1 mL; Type: Sputum; Container: Sterile container; Transport Temperature: Refrigerated</td>
</tr>
<tr>
<td><strong>Stability</strong></td>
<td>24 hours at ambient temperature, 7 days at 2-8°C or 30 days frozen (-20°C or -70°C)</td>
</tr>
<tr>
<td><strong>Billing Code</strong></td>
<td>87814</td>
</tr>
<tr>
<td><strong>CPT Codes</strong></td>
<td>87798(x1)</td>
</tr>
</tbody>
</table>

## References


## Technical Information Contacts:

Colleen Starkey  
216.444.8792  
starkec@ccf.org

Sherilynn Vogel  
216.444.8222  
vogels@ccf.org

## Scientific Information Contact:

Gary Procop, MD  
216.444.5879  
procopg@ccf.org